CD8-Positive T-Cells Are Key Immune Cells for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-10-01 DOI:10.21873/anticanres.17281

Natsuki Uenaka, Eiichi Sato, Yoshiya Horimoto, Saori Kawai, Mariko Asaoka, Hiroshi Kaise, Kimito Yamada, Takashi Ishikawa

{"title":"CD8-Positive T-Cells Are Key Immune Cells for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.","authors":"Natsuki Uenaka, Eiichi Sato, Yoshiya Horimoto, Saori Kawai, Mariko Asaoka, Hiroshi Kaise, Kimito Yamada, Takashi Ishikawa","doi":"10.21873/anticanres.17281","DOIUrl":null,"url":null,"abstract":"Background/aim: Patients with triple-negative breast cancer (TNBC) who obtain a pathological complete response (pCR) after neoadjuvant chemotherapy have an improved prognosis. Lymphocyte-predominant breast cancer is more likely to respond to neoadjuvant chemotherapy. Here, we investigated the correlation between tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsy specimens from patients with TNBC in relation to response to NAC.Patients and methods: The level of infiltration by immune cells expressing immune cell lineage surface markers (CD8, CD4, CD19, CD14, CD11c, and CD11b) in biopsy specimens from 52 patients with TNBC was examined using multispectral immunofluorescent labelling.Results: The level of CD8-positive TILs was significantly higher in patients with a pCR (p=0.045). The Cox proportional hazard model confirmed that lymph node involvement was associated with poorer disease-free survival (p=0.008). A high level of CD8-positive TILs was related to significantly prolonged disease-free survival in patients with node-positive TNBC (p=0.018).Conclusion: Assessing infiltration by CD8-positive TILs in the primary tumor is a useful biomarker to predict pCR and improved outcome in patients with node-positive TNBC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4525-4536"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17281","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Patients with triple-negative breast cancer (TNBC) who obtain a pathological complete response (pCR) after neoadjuvant chemotherapy have an improved prognosis. Lymphocyte-predominant breast cancer is more likely to respond to neoadjuvant chemotherapy. Here, we investigated the correlation between tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsy specimens from patients with TNBC in relation to response to NAC.

Patients and methods: The level of infiltration by immune cells expressing immune cell lineage surface markers (CD8, CD4, CD19, CD14, CD11c, and CD11b) in biopsy specimens from 52 patients with TNBC was examined using multispectral immunofluorescent labelling.

Results: The level of CD8-positive TILs was significantly higher in patients with a pCR (p=0.045). The Cox proportional hazard model confirmed that lymph node involvement was associated with poorer disease-free survival (p=0.008). A high level of CD8-positive TILs was related to significantly prolonged disease-free survival in patients with node-positive TNBC (p=0.018).

Conclusion: Assessing infiltration by CD8-positive TILs in the primary tumor is a useful biomarker to predict pCR and improved outcome in patients with node-positive TNBC.

查看原文本刊更多论文

CD8阳性T细胞是预测三阴性乳腺癌新辅助化疗疗效的关键免疫细胞

背景/目的：新辅助化疗后获得病理完全反应（pCR）的三阴性乳腺癌（TNBC）患者预后较好。淋巴细胞占优势的乳腺癌更有可能对新辅助化疗产生反应。在此，我们研究了TNBC患者治疗前活检标本中肿瘤浸润淋巴细胞（TILs）与新辅助化疗反应之间的相关性：采用多谱免疫荧光标记法检测了52例TNBC患者活检标本中表达免疫细胞系表面标记（CD8、CD4、CD19、CD14、CD11c和CD11b）的免疫细胞的浸润水平：结果：CD8阳性TIL的水平在pCR患者中明显更高（p=0.045）。Cox比例危险模型证实，淋巴结受累与较差的无病生存率相关（p=0.008）。高水平的CD8阳性TIL与结节阳性TNBC患者无病生存期显著延长有关（p=0.018）：结论：评估CD8阳性TIL在原发肿瘤中的浸润是预测结节阳性TNBC患者pCR和改善预后的有用生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.